Cingulate Inc.
corporate_fare Company Profile
Cingulate Inc. (NASDAQ:CING) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 37 items for CING at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-13, rated 8/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for CING spans 10-Q, 8-K, DEF 14A, DEFA14A.
Recent high-impact activity:
- Cingulate Q3 10-Q: $23.2M Cash, $7.7M Quarterly Loss, Going Concern Restated
- Cingulate Posts Q3 Loss, $23.2M Cash, Targets Dec 2026-Jan 2027 NDA Resubmission
- Cingulate Sets Dec 2026-Jan 2027 CTx-1301 NDA Resubmission Window After CRL
- Cingulate Q2 10-Q: $28.4M Cash, Going Concern Doubt, FDA CRL Details
- Cingulate Reports Q2 2026 Results: $28.4M Cash Runway Through Mid-2027, NDA Resubmission in Progress
Financial Snapshot
Short Interest & Short Volume
7.52 days to coverFINRA reported short interest of 1,037,583 shares in CING as of the October 30, 2026 settlement, a 2.0% increase from the prior period — about 7.5 days to cover at its recent average daily volume. On November 20, 2026, 33.9% of CING volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Dilution Risk
Low riskFiling-implied dilution signals for CING, detected from its recent SEC filings · based on capital-structure filings through 2026-11-13.
Maxim Added as Second ATM Agent · ATM Capacity Unchanged at $100M
A filing-implied signal, not a realized share count. How Wiseek tracks dilution →